CD31 shed as a molecular target for imaging of inflammation
US11098124B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 3, 2017 |
| Grant date | Aug 24, 2021 |
| Priority date | — |
| Expiry date | May 3, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7095
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.